Stomach cancer gets a triple punch of therapy

Chalabi, Myriam

doi:10.1038/d41586-021-03458-7

NEWS AND VIEWS
15 December 2021

Stomach cancer gets a triple punch of therapy

Harnessing immune cells to target tumours is a growing trend. The results of a clinical trial combining such treatment with other standard therapies for gastric cancer have altered medical practice — and more changes are to come.

Myriam Chalabi ⁰

Myriam Chalabi
1. Myriam Chalabi is in the Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam 90203, the Netherlands.
View author publications

You can also search for this author in PubMed Google Scholar

Access through your institution

Buy or subscribe

Gastric cancer is a highly aggressive disease. Writing in Nature, Janjigian et al.¹ present clinical data that point to a way to improve outcomes for people who have this type of tumour.

Access options

Access through your institution

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature 600, 608-609 (2021)

doi: https://doi.org/10.1038/d41586-021-03458-7

References

Janjigian, Y. Y. et al. Nature 600, 727–730 (2021).
Article Google Scholar
Janjigian, Y. Y. et al. Lancet 398, 27–40 (2021).
PubMed Article Google Scholar
Baselga, J. et al. J. Clin. Oncol. 14, 737–744 (1996).
PubMed Article Google Scholar
Slamon, D. J. et al. N. Engl. J. Med. 344, 783–792 (2001).
PubMed Article Google Scholar
Bang, Y.-J. et al. Lancet 376, 687–697 (2010).
PubMed Article Google Scholar
Gall, V. A. et al. Cancer Res. 77, 5374–5383 (2017).
PubMed Article Google Scholar
Shitara, K. et al. N. Engl. J. Med. 382, 2419–2430 (2020).
PubMed Article Google Scholar